Group 1 - The company has received the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution from the National Medical Products Administration [1][4] - The drug is approved for the treatment of chronic constipation and fecal impaction [3] - The product will enhance the company's "One Elderly" strategy, expanding its product matrix in the elderly care sector [4][2] Group 2 - The drug is classified as a Class 3 chemical drug and is a prescription medication [7] - The main components of the drug include Polyethylene Glycol 3350, Sodium Chloride, Potassium Chloride, and Sodium Bicarbonate [7] - The company plans to initiate mass production and market launch of the new product, leveraging its brand and marketing network [4][2]

Group 1 - The core point of the article is that Kewang Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its compound polyethylene glycol (3350) electrolyte oral solution [2] Group 2 - The approval signifies a regulatory milestone for the company's subsidiary, enhancing its product portfolio in the pharmaceutical market [2] - This development may lead to increased market opportunities and potential revenue growth for the company [2]

Group 1 - The company,葵花药业, announced that its subsidiary has received a drug registration certificate from the National Medical Products Administration for a compound polyethylene glycol (3350) electrolyte oral solution [1] - The drug is classified as a Class 3 chemical drug and is a prescription medication, with the approval number H20263376 [1] - The main components of the drug include polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate, and it is indicated for the treatment of chronic constipation and fecal impaction [1] Group 2 - The drug is packaged in a specification of 25ml per bag, and the marketing authorization holder and manufacturer is 葵花药业集团 (唐山) 生物制药有限公司 [1]

Group 1 - The core point of the article is that ST Huluwawa's wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate for the compound polyethylene glycol (3350) electrolyte oral solution from the National Medical Products Administration [1] Group 2 - The drug is named compound polyethylene glycol (3350) electrolyte oral solution [1]

Core Viewpoint - ST Huluwawa (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution, which is indicated for the treatment of chronic constipation and fecal impaction [1] Company Summary - ST Huluwawa's subsidiary Guangxi Weiwei has successfully obtained regulatory approval for a new product, enhancing its portfolio in the gastrointestinal treatment market [1] - The approved product, compound polyethylene glycol (3350) electrolyte oral solution, targets a significant health issue, chronic constipation, which may lead to increased market demand [1]

Core Viewpoint - The company ST HuLuWa has received approval from the National Medical Products Administration for its subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. to market a new oral solution for chronic constipation and fecal impaction, enhancing its product line [1] Group 1 - The approved drug is a compound polyethylene glycol (3350) electrolyte oral solution, developed by Norgine, and contains active ingredients such as polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate [1] - The company has invested a total of RMB 762,100 in research and development for this drug [1] - The approval of the drug registration certificate will further enrich the company's product offerings [1]